Trial Profile

Phase 1/2, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 in Addition to Standard of Care for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALVR 106 (Primary)
Indications Influenza virus infections; Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
Focus Adverse reactions; Proof of concept; Therapeutic Use

02 Feb 2024 Status changed from recruiting to discontinued due to Strategic sponsor decision.
02 Nov 2023 According to an AlloVir media release, data from this trial will be shared at a future scientific congress in the first quarter of 2024.
03 Aug 2023 According to an AlloVir media release, the company has completed enrollment in the dose escalation (Part A) portion of this trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com